Supreme Court Asked To Consider Pre-emption In Drug Vs. Cosmetic Litigation
This article was originally published in The Tan Sheet
Executive Summary
The Supreme Court asks the Solicitor General for an amicus in a case examining whether FDA regulation pre-empts state litigation on the cosmetics/drugs regulatory divide. The case could have implications for the personal care industry as states increasingly claim oversight by clarifying FDA’s division between drugs and cosmetics.
You may also be interested in...
In Brief: Coty Eyes OPI Growth; RevitaLash Is Back; Garnier Pulled From China
Coty aims to drive development of its OPI nail brand in the U.K. with the acquisition of distributor Lena White. More news in brief.
In Brief
Latisse maker Allergan prevails in California district court over cosmetic eyelash-enhancement marketer Athena Cosmetics, which has been enjoined from selling RevitaLash in the U.S. More news in brief.
Jan Marini Focused On Damage Control Following FDA Seizure Of Eyelash Item
Jan Marini issued a statement Nov. 16 stressing that its Age Intervention Eyelash product has not been manufactured or distributed since September of last year, in response to a release from FDA announcing seizure of the "potentially harmful" product